Epithalon
The pineal tetrapeptide whose telomere data comes from cells, not people
Epithalon is a four-amino-acid peptide built on the composition of a bovine pineal extract. In cell cultures it switched on telomerase and lengthened telomeres; in mice it extended the lives of the longest survivors and cut some tumours. What it does in people has barely been tested, and most of the work comes from the lab that made it.
What is it?
Epithalon, also sold as Epitalon or Epithalone, is a tetrapeptide: alanine, glutamic acid, aspartic acid and glycine, abbreviated AEDG. According to a 2025 review, it was synthesised from the amino-acid composition of epithalamin, a peptide extract of bovine pineal gland, and only later found in the gland's own polypeptide mix. It came out of Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, and most of the studies below come from that group and its collaborators.
The claim that made it famous is about telomeres. In 2003 the group reported that adding epithalon to telomerase-negative human fetal fibroblasts switched on the enzyme's catalytic subunit, raised telomerase activity and lengthened telomeres. A 2025 study found dose-dependent lengthening in normal human epithelial cells and fibroblasts too, through more hTERT and telomerase, and something less welcome in two breast-cancer lines, whose telomeres also grew, through the ALT pathway. All of this happened in dishes. None of the carded studies measured telomeres in people who took it.
The animal record is more mixed than the marketing. In the longest mouse study, a lifetime of monthly injections did not change average lifespan, but the longest-lived tenth of the mice lived 13.3% longer, bone-marrow chromosome damage fell 17.1%, and leukaemia was six times less common. In mice bred to develop HER-2/neu breast cancer, average lifespan rose 13.5% and tumours were fewer. Several headline lifespan figures, 11–31% across flies, mice and rats, come from epithalamin, the extract, rather than epithalon itself.
What is missing is the part that matters to a person deciding whether to use it: controlled human trials of the synthetic peptide, with numbers, from independent groups. The largest human study, a 12-year randomised trial reporting 28% fewer deaths, used epithalamin in elderly heart patients, and its abstract gives no group sizes. In the US, the Pharmacy Compounding Advisory Committee voted on July 24, 2026 to recommend adding epithalon to the 503A bulks list; FDA has not acted, so pharmacies still cannot compound it (as of September 26, 2026).
Mechanism of Action
Nobody has pinned down how a four-residue peptide produces the range of effects claimed for it, and the 2025 review says as much: the known actions may not be its only ones, and structural and physico-chemical studies of the molecule remain scarce. What the abstracts do describe falls into four groups, each resting mostly on cell or animal work.
The telomere steps come from cell cultures, where cancer cells lengthened their telomeres too. The lifespan steps are from mice; the long human trial used the parent extract, not epitalon.
Each step is tagged with where it was shown. A dashed red arrow marks a link the evidence does not establish.
The pathway in words
- Epitalon. A synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, made from the composition of epithalamin, a bovine pineal extract. Shown in: review. Source: PubMed 40141333.
- Telomerase in cells. In telomerase-negative human fetal fibroblasts it induced telomerase's catalytic subunit, enzyme activity and telomere elongation. Shown in: cells. Source: PubMed 12937682.
- Cancer cells too. Normal cells lengthened telomeres through telomerase; two breast-cancer lines lengthened theirs through a telomerase-free route, ALT. Shown in: cells. Source: PubMed 40908429.
- Lifespan in mice. Lifetime monthly injections in 54 mice left average lifespan unchanged; the longest-lived 10% lived 13.3% longer. Shown in: animals. Source: PubMed 14501183.
- never tested with epitalon. Longer life in people. The only long human trial used epithalamin, the bovine extract, not synthetic epitalon. Shown in: people. Source: PubMed 17426848.
Telomerase activation
In telomerase-negative human fetal fibroblasts, epithalon induced expression of telomerase's catalytic subunit, raised the enzyme's activity and lengthened telomeres (2003). A 2025 study reported dose-dependent telomere lengthening in normal human cells through hTERT mRNA and telomerase, and lengthening in breast-cancer cells through ALT, the telomerase-independent route. That second result is why 'telomerase activator' is not automatically good news.
Pineal and melatonin
Its parent extract, epithalamin, increased melatonin synthesis in rats, and the 2025 review lists a direct influence on melatonin synthesis among epithalon's documented actions. This is the link behind its 'pineal regulator' label. How much of it carries over from the extract to the synthetic tetrapeptide, and from rodents to people, is not established.
Gene expression
In human gingival mesenchymal stem cells, AEDG raised the protein and mRNA levels of four neuronal-differentiation markers, Nestin, GAP43, β-tubulin III and doublecortin, by 1.6 to 1.8 times. Molecular modelling suggested it binds histones H1/3 and H1/6 at DNA-contacting sites, which the authors propose as an epigenetic mechanism. Modelling generates hypotheses; it does not confirm them.
Oxidative stress
In mouse oocytes aged in culture, 0.1 mM epitalon lowered reactive oxygen species, reduced spindle defects, raised mitochondrial membrane potential and cut apoptosis at 24 hours. Epithalamin inhibited free-radical processes in rats and fruit flies, and the review groups antioxidant, neuroprotective and antimutagenic activity together as the likely source of its geroprotective results.
Published Research
PubMed returns roughly 235 records for the name, and most describe cells, rodents or the parent extract. The twelve studies below were chosen because their abstracts say what was measured and by how much. Each card names what the study used: several of the most-quoted numbers come from epithalamin, not epithalon, and the cell studies say nothing about dosing a person.
Telomerase switched on in human fetal fibroblasts
The founding telomere result. Adding epithalon to cultures of telomerase-negative human fetal fibroblasts induced expression of telomerase's catalytic subunit, measurable telomerase activity and telomere elongation. The authors read this as reactivation of the telomerase gene and a possible route to extending the lifespan of cells and whole organisms. The abstract reports no doses or effect sizes, and it is one short paper from the developers' group.
Longer telomeres in normal and breast-cancer cells
Normal epithelial cells, fibroblasts and two breast-cancer lines (21NT and BT474) were treated with epitalon. Normal cells showed dose-dependent telomere lengthening through more hTERT mRNA and telomerase activity, with only a minor rise in ALT activity. The cancer lines lengthened their telomeres too, through ALT activation. The journal published a correction to the paper later in 2025; the correction notice's abstract does not say what changed.
Donor lymphocytes: telomeres moved both ways
Stimulated blood lymphocytes from 11 men, five aged 18–22 and six aged 49–54, were incubated with the peptide. Relative telomere length changed significantly in 7 of the 11: it rose in five, by 18% to 156%, and fell in two, by 37% and 15%. The authors describe a tendency to normalisation, with short telomeres lengthening and long ones shortening. Eleven donors, one experiment, cells rather than people.
Neuronal markers raised in human stem cells
In human gingival mesenchymal stem cells, AEDG increased synthesis of four neurogenic differentiation markers, Nestin, GAP43, β-tubulin III and doublecortin, and raised their mRNA 1.6 to 1.8 times. Computer modelling suggested the peptide binds histones H1/3 and H1/6 at sites that contact DNA, which the authors offer as an epigenetic mechanism. It is a cell-differentiation result, not evidence of a brain effect in people.
Retinitis pigmentosa: rats, then patients
In Campbell rats, which inherit retinal degeneration, epitalon preserved retinal structure and improved its electrical and functional activity. The abstract then reports a positive clinical effect in 90% of patients with degenerative retinal disease who were treated, but gives no number of patients, no comparison group and no definition of 'positive'. As human evidence it is a claim to follow up, not a result to rely on.
Twelve-year trial of the parent extract
Elderly patients with coronary disease and accelerated cardiovascular ageing took part in a 12-year randomised study of epithalamin, the bovine pineal extract, not synthetic epithalon. The treated group had lower functional age, better exercise tolerance and 28% fewer deaths, with half the cardiovascular mortality and half the heart failure and respiratory disease of controls on the same basic therapy. The abstract gives no group sizes or blinding details.
Lifetime injections in SHR mice
From three months of age until death, 54 female mice received 1 µg of epitalon (about 30–40 µg/kg) under the skin on five consecutive days a month; 54 received saline. Average lifespan, body weight and food intake did not change. The longest-lived 10% lived 13.3% longer, maximum lifespan rose 12.3%, bone-marrow chromosome aberrations fell 17.1% and leukaemia was six times less frequent. Total tumour incidence did not change.
HER-2/neu mice: longer lives, fewer breast tumours
Female transgenic mice carrying the HER-2/neu breast-cancer gene were injected five times a week from their second month until death, at a dose the abstract gives as 1 mg. Average and maximum lifespan rose 13.5% and 13.9%. Mice free of breast tumours were 3.7 times more common, lung metastases were 1.6 times rarer, and animals with six or more tumours fell threefold. The authors link this to suppressed HER-2/neu expression.
No metastases in treated C3H/He mice
One-year-old female C3H/He mice were injected with 0.1 µg of epitalon five times a week for six and a half months, and the authors saw no toxic effects. Fewer treated mice developed malignant tumours, and none developed metastases, against three of nine tumour-bearing controls. Most tumours in both groups arose in the mammary glands and ovaries. The abstract does not give total group sizes, which limits how far the comparison can be pushed.
Ageing mouse eggs protected in culture
Mouse oocytes left to age after ovulation were cultured with 0.1 mM epitalon for up to 24 hours. Reactive oxygen species fell, spindle defects and abnormal cortical-granule distribution became less common at 12 and 24 hours, mitochondrial membrane potential and mitochondrial DNA copy number rose, and fewer oocytes died by apoptosis at 24 hours. It is a fertility-lab finding about cells in a dish.
Parent extract across three species
Epithalamin, the pineal extract, raised mean lifespan by 11–31% in female fruit flies, two mouse strains and rats. Mortality rate fell 52% in flies and rats and 27% in C3H/Sn mice, but did not change in SHR mice. The extract increased melatonin synthesis in rats and inhibited free-radical processes, which the authors propose as the reason. These are extract results, and they are the source of many 'epithalon extends life' claims.
A quarter-century of Epitalon research, reviewed
This review of in vitro, in vivo and in silico work describes geroprotective and neuroendocrine effects attributed to antioxidant, neuroprotective and antimutagenic activity, with documented influences on melatonin synthesis, interleukin-2 mRNA and enzymes including telomerase. It is candid about the gaps: it is uncertain whether these are the peptide's only mechanisms, and structural and physico-chemical studies of the molecule remain limited.
What people say, and what was measured
Epithalon's claims are the boldest on this site: longer telomeres, slower ageing, a longer life. Nearly all of the research comes from one group in St Petersburg, and the distinction that matters most is between epitalon, the four-amino-acid peptide sold today, and epithalamin, the pineal gland extract used in the long human studies.
It lengthens your telomeres and switches telomerase back on.
Heard in: International Journal of Molecular Sciences, Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties, which records that epitalon enhances telomerase activity among its reported effects (read October 1, 2026). Source
In cell culture. Adding epitalon to human fetal fibroblasts, which make no telomerase, switched the enzyme on and lengthened telomeres. A 2025 study repeated it in normal cells, and found that in breast cancer cell lines telomeres also lengthened, through an alternative mechanism specific to the cancer cells. No study has measured a person's telomeres after taking it. PMID: 12937682, 40908429
Shown in animals or cells onlyPeople who took it lived longer, with fewer deaths over twelve years.
Heard in: Bulletin of Experimental Biology and Medicine, Geroprotective effect of epithalamine in elderly subjects with accelerated aging of the cardiovascular system, which reports 28% fewer deaths at twelve years in the treated group (read October 1, 2026). Source
That twelve-year result is real, and it is not about the peptide sold today. It used epithalamine, a preparation extracted from animal pineal glands, in elderly patients with coronary disease; the synthetic tetrapeptide epitalon is a different substance. Within that study, functional age and cardiovascular ageing fell and exercise tolerance rose. No long-term human study of synthetic epitalon exists. PMID: 17426848
Tested in people; mixedIt extends lifespan, as the animal work shows.
Heard in: Grey Peptides listing review, October 1, 2026: listings present epitalon as a life-extension and anti-ageing peptide. Sellers are not named.
The animal results are more specific than the claim. Epithalamin, the extract, raised mean lifespan 11 to 31% in flies, two strains of mice and rats. Epitalon, the peptide, did not change mean lifespan in female mice at all: it extended the lifespan of the last 10% of survivors by 13.3% and maximum lifespan by 12.3%, slowed the loss of oestrous function and cut chromosome damage. Those are different results from different substances. PMID: 9701766, 14501183
Shown in animals or cells onlyBecause it restores telomeres, it protects against cancer.
Heard in: International Journal of Molecular Sciences, Overview of Epitalon, which reviews the anti-tumour findings reported for the peptide alongside its other proposed mechanisms (read October 1, 2026). Source
In mice, epitalon reduced breast tumours in a cancer-prone strain and did not raise overall spontaneous tumour rates, while cutting leukaemia six-fold in another. Against that, the 2025 cell study found epitalon lengthening telomeres in breast cancer cells through a mechanism those cells use to survive. The animal and cell results point in opposite directions, and nothing has been measured in a person. PMID: 12459848, 14501183, 40908429
Shown in animals or cells onlyEach claim is quoted from where it is said, never from a seller, and checked as of October 1, 2026 against the studies listed below.
Dosing Data
No published trial in our evidence set establishes a human dose for synthetic epithalon. The community figures below come from forums and vendor charts, and the dataset marks them as such. The animal studies dosed micrograms: 1 µg per mouse, about 30–40 µg/kg, in the longest lifespan study, and 0.1 µg per mouse in another. The milligram amounts people use are a separate, untested choice.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
→ Full Epithalon dosage guide — why the community cycles look the way they do, and how far they sit from what the animal studies dosed
Side Effects & Contraindications
Reported Side Effects
No trial of synthetic epithalon in our evidence set reports an adverse-event table, so there is no human side-effect profile to quote. What the abstracts say about safety comes from animals, and the practical risks come from how research peptides are made and sold.
Contraindications & Cautions
Without human safety data, these are cautions drawn from what the peptide is reported to do rather than from observed harm. The first matters most: keeping telomeres long is also what most cancers do, and a 2025 study found the peptide lengthened telomeres in breast-cancer cells as well as normal ones.
Legal Status
Epithalon is not approved as a medicine in any of the jurisdictions below. It is sold as a research chemical, and in the US it sits in a specific limbo: out of Category 2, recommended by FDA's advisory committee, and still not something a pharmacy may compound. Status as of September 26, 2026.
Frequently Asked Questions
?Is epithalon the same as epithalamin?
No. Epithalamin is a peptide extract of bovine pineal gland. Epithalon, also spelled Epitalon, is the synthetic four-amino-acid peptide (AEDG) designed from the extract's amino-acid composition. The distinction matters because several of the most-quoted results, including the 11–31% lifespan gains across species and the 12-year human mortality study, were produced with the extract, not the synthetic peptide.
?Does epithalon lengthen telomeres in people?
That has not been shown. The telomere results come from cells: human fetal fibroblasts in 2003, normal and cancer cell lines in 2025, and lymphocytes from 11 donors in 2019, where telomeres lengthened in five and shortened in two. None of the studies on this page measured telomeres in people who took the peptide.
?Does it extend lifespan?
In some mouse studies, partly. In the lifetime study in SHR mice, average lifespan did not change, while the longest-lived tenth lived 13.3% longer. Transgenic breast-cancer mice lived 13.5% longer on average. The larger 11–31% figures come from the extract. There is no lifespan evidence in humans for the synthetic peptide.
?Is epithalon safe?
No one knows for people. Mouse studies report no toxic effects at microgram doses, but there are no published adverse-event data in humans, community doses are in milligrams, and research-chemical vials are unregulated. The theoretical concern worth taking seriously is cancer: in a 2025 cell study it lengthened telomeres in breast-cancer cells too.
?Can a US pharmacy compound epithalon?
Not as of September 26, 2026. FDA's advisory committee voted on July 24, 2026 to recommend adding it to the 503A bulks list, but only FDA can add it, through rulemaking, and it has not. Until then it is on no list that lets a 503A pharmacy compound it.
?Who has studied epithalon?
Mostly the St. Petersburg group that developed it and its collaborators, often in Russian journals published in English translation. The two most recent cell studies on this page appeared in international journals (Aging, 2022; Biogerontology, 2025). What the field still lacks is controlled human trials of the synthetic peptide.
References
- [pubmed] Khavinson VKh, et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med, 2003;135(6):590-2. PMID: 12937682.
- [pubmed] Al-Dulaimi S, et al. "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." Biogerontology, 2025;26(5):178. PMID: 40908429.
- [pubmed] Khavinson VK, et al. "Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes." Bull Exp Biol Med, 2019;168(1):141-144. PMID: 31761987.
- [pubmed] Khavinson V, et al. "AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism." Molecules, 2020;25(3). PMID: 32019204.
- [pubmed] Khavinson V, et al. "Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa." Neuro Endocrinol Lett, 2002;23(4):365-8. PMID: 12195242.
- [pubmed] Korkushko OV, et al. "Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging." Bull Exp Biol Med, 2006;142(3):356-9. PMID: 17426848.
- [pubmed] Anisimov VN, et al. "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology, 2003;4(4):193-202. PMID: 14501183.
- [pubmed] Anisimov VN, et al. "Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice." Bull Exp Biol Med, 2002;134(2):187-90. PMID: 12459848.
- [pubmed] Kossoy G, et al. "Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice." In Vivo, 2006;20(2):253-7. PMID: 16634527.
- [pubmed] Yue X, et al. "Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro." Aging (Albany NY), 2022;14(7):3191-3202. PMID: 35413689.
- [pubmed] Anisimov VN, et al. "Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats." Mech Ageing Dev, 1998;103(2):123-32. PMID: 9701766.
- [pubmed] Araj SK, et al. "Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties." Int J Mol Sci, 2025;26(6). PMID: 40141333.
Sources & Citations
Every citation on this page is PubMed-indexed and has been checked against its record: not just that the identifier resolves, but that the paper is about what the sentence beside it claims. Where a study used epithalamin, the pineal extract, rather than synthetic epithalon, the card says so. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.